A Phase I Open Label Trial of Continuous Dosing With BIBW 2992 Combined With Paclitaxel and BIBW 2992 Combined With Paclitaxel and Bevacizumab, BIBW 2992 Combined With Carboplatin and BIBW 2992 Combined With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumours

Boehringer Ingelheim

Description

The main purpose of this study is to assess the optimum dose of the following medications when they are given together: - BIBW 2992 and paclitaxel (Taxol) - BIBW 2992 and paclitaxel and bevacizumab (Avastin) - BIBW 2992 and carboplatin - BIBW 2992 and paclitaxel and carboplatin The effect of the different drug combinations will also be assessed.

Citations (0)

No citations found

It looks like this dataset has no citations.

Mentions (0)

No mentions found

It looks like this dataset has not been mentioned in any sources.

Metrics

Dataset Index

0.2

FAIR Score

31%

Citations

Mentions

Metrics Over Time

Publication Details

DOI

10.25934/00005250

Publisher

Vivli

License

Study data may be accessed by completing a request form at https://vivli.org. It will then be reviewed according to the data contributor’s governance policy, see https://vivli.org/members/ourmembers/ for Vivli member’s review process. If approved, use of the data is governed by the data use agreement at https://vivli.org/resources/vivli-data-use-agreement/

Assigned Domain

Subfield

Molecular Biology

Field

Biochemistry, Genetics and Molecular Biology

Domain

Life Sciences

Confidence Score

41%

Source

Scholar Data Model

Keywords

Conditions: NeoplasmsInterventions: PaclitaxelInterventions: CarboplatinInterventions: BIBW 2992Interventions: BIBW2992Interventions: Bevacizumab

Normalization Factors

53.85

CTw

1.00

MTw

1.00